Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 28;226(7):1195-1199.
doi: 10.1093/infdis/jiac190.

Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses

Laila Sara Arroyo Mühr  1 , Carina Eklund  1 , Camilla Lagheden  1 , Tiina Eriksson  2 , Ville N Pimenoff  1   2 , Penelope Gray  3   4 , Matti Lehtinen  1   2 , Joakim Dillner  1   5
Affiliations

Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses

Laila Sara Arroyo Mühr et al. J Infect Dis. .

Abstract

For head-to-head comparison of human papillomavirus (HPV) antibody levels induced by different vaccines, 25-year-old vaccine-naive women were given either the bivalent (n = 188) or the nonavalent HPV vaccine (n = 184). Six months after vaccination antibodies against pseudovirions from 17 different HPV types (HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68/73) were measured. Antibodies against HPV16/18 were higher after bivalent HPV vaccination (mean international units [IU] 1140.1 and 170.5 for HPV16 and 18, respectively) than after nonavalent vaccination (265.1 and 22.3 IUs, respectively). The bivalent vaccine commonly induced antibodies against the nonvaccine HPV types 31/33/35/45 or 58. The nonavalent vaccine induced higher antibodies against HPV6/11/31/33/45/52/58 and 35.

Keywords: antibody; bivalent; human papillomavirus; international units; nonavalent; vaccine.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. J. D. and M. L. have previously received grants for HPV vaccination studies from Merck & Co. Inc. (J. D. and M. L.) and GSK Biologicals (M. L.). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Flowchart of the study enrollment and participation.
See this image and copyright information in PMC

References

    1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans . Human papillomaviruses. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans, Vol 90. Lyon, France: IARC, 2007. - PubMed
    1. Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 2013; 10:400–10. - PubMed
    1. Huh WK, Joura EA, Giuliano AR, et al. . Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet 2017; 390:2143–59. - PubMed
    1. Kjaer SK, Nygard M, Sundstrom K, et al. . Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine 2020; 23:100401. - PMC - PubMed
    1. Lei J, Ploner A, Elfstrom KM, et al. . HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020; 383:1340–8. - PubMed

Publication types